



EXECUTIVE SUMMARY

January 24, 2025

K2X Technology & Life Science, Inc. (“K2X”) is a startup investment fund based in Silicon Valley, with a unique and safer way for global investors to access top-tier startups via a liquid and highly-diversified portfolio. We are a new way for the world to invest in pure innovation. Here’s what sets us apart:

- **Innovative Investment Model:** K2X provides a non-correlated, high-return, low-risk, and highly liquid (assuming NASDAQ IPO completed) investment opportunity.
- **Rigorous Vetting Process:** Each investment undergoes two-step vetting. First, a lead and trusted investor, such as an angel group, evaluates, sets terms and invests. Then, our 100+ world-class advisors, all of whom are investors, conducts a second vetting. We then review the double-vetted global companies and select the best for adding to our portfolio.
- **Extensive Portfolio:** K2X seeks to create an ETF-like vehicle whose assets are a large number of startups. Investing since 2018, K2X has built a portfolio with 90 startups, 75% of which are in life sciences. Our investments span the US, Canada, Israel, and India.
- **Proven Success:** Superior results, including budding unicorns and three successful exits. We anticipate an annual IRR of 20-30% measured over a number of years.
- **Investor-Friendly Structure:** K2X investors are stockholders with no annual cash calls, management fees, or carry. Ownership is straightforward—if you own 1% of K2X, you own 1% of all our assets, including future investments.
- **Aligned Interests:** Our management is only incentivized through stock options, ensuring their goals totally align with our investors.
- **Future Goals:** We aim to list on NASDAQ in the first half of 2025, creating “The ETF of Startups” for global investors. We’re raising a \$5 million pre-IPO convertible debt round with interest and a 25% discount on IPO conversion, and 4X participation rights.

About K2X

Incorporated in Delaware, K2X focuses on creating a diversified and rigorously vetted startup portfolio, establishing a new non-correlated asset class. To date, we’ve raised \$18 million through Series A and B preferred shares, common shares, and convertible debt.

Our double-vetting methodology ensures we select startups most likely to succeed. Notably, our portfolio company BasePaws, acquired by Zoetis, provided a 12X return on our initial investment. And two budding unicorns, Promaxo and Neuro42.

We have engaged bankers Ladenburg Thalmann and Northland Capital Markets to co-lead the \$50 million NASDAQ IPO and have engaged Eversheds Sutherland as the legal team. K2X is in the process of being audited by BPM and our plan is to distribute excess cash from exits, if any, quarterly to shareholders. With a proven pre-IPO business model consisting of many private investments, K2X is ready to scale up post-IPO with more, larger and later stage deals. **K2X is an evergreen startup fund.**

K2X is redefining startup investing!

www.k2x.capital

Paul M. Russo, PhD - CEO

c: +1 (408) 605-7695
paul@k2x.capital

www.k2x.capital

Simon Westbrook - CFO

c: +1 (408) 313-5830
simon@k2x.capital